A systematic review of the prevalence of anxiety among the general population during the COVID-19 pandemic.
Anxiety
Covid-19
Meta-analysis
People
Systematic review
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
received:
23
04
2021
revised:
25
05
2021
accepted:
25
06
2021
pubmed:
12
7
2021
medline:
11
8
2021
entrez:
11
7
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic has had an adverse effect on the mental health of population worldwide. This study was conducted to systematically review the existing literature to identify the individuals at higher risk of anxiety with a view to provide targeted mental health services during this outbreak. In this study, the studies focusing on anxiety prevalence among the general population during the COVID-19 pandemic were searched in the PubMed, EMBASE, Scopus, Web of Science (WoS) and Google Scholar from the beginning of Covid-19 pandemic to February 2021. 103 studies constituting 140732 people included in the review. The findings showed that anxiety prevalence was 27.3% (95% CI, 23.7%; 31.2%) among general population while the prevalence in COVID-19 patients was 39.6% (95% CI, 30.1%; 50.1%). Anxiety was significantly higher among females and older adults (p≤0.05). In addition Europe revealed the highest prevalence of anxiety 54.6% (95% CI, 42.5%; 66.2%) followed by America 31.5% (95% CI, 19%; 47.5%) and Asia 28.3% (95% CI, 20.3%; 38%). In the general population the highest prevalence of anxiety was in Africa 61.8% (95% CI, 57%-66.4%) followed by America 34.9% (95% CI, 27.7%-42.9%), Europe 30.7% (95% CI, 22.8%-40%) and Asia 24.5% (95% CI, 20.7%-28.9%). During the COVID-19 crisis, through identifying those who are more likely to be suffered from mental disorders at different layers of populations, it would be possible to apply appropriate supportive interventions with a view to provide targeted mental health services during the outbreak.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has had an adverse effect on the mental health of population worldwide. This study was conducted to systematically review the existing literature to identify the individuals at higher risk of anxiety with a view to provide targeted mental health services during this outbreak.
METHODS
In this study, the studies focusing on anxiety prevalence among the general population during the COVID-19 pandemic were searched in the PubMed, EMBASE, Scopus, Web of Science (WoS) and Google Scholar from the beginning of Covid-19 pandemic to February 2021.
RESULTS
103 studies constituting 140732 people included in the review. The findings showed that anxiety prevalence was 27.3% (95% CI, 23.7%; 31.2%) among general population while the prevalence in COVID-19 patients was 39.6% (95% CI, 30.1%; 50.1%). Anxiety was significantly higher among females and older adults (p≤0.05). In addition Europe revealed the highest prevalence of anxiety 54.6% (95% CI, 42.5%; 66.2%) followed by America 31.5% (95% CI, 19%; 47.5%) and Asia 28.3% (95% CI, 20.3%; 38%). In the general population the highest prevalence of anxiety was in Africa 61.8% (95% CI, 57%-66.4%) followed by America 34.9% (95% CI, 27.7%-42.9%), Europe 30.7% (95% CI, 22.8%-40%) and Asia 24.5% (95% CI, 20.7%-28.9%).
CONCLUSION
During the COVID-19 crisis, through identifying those who are more likely to be suffered from mental disorders at different layers of populations, it would be possible to apply appropriate supportive interventions with a view to provide targeted mental health services during the outbreak.
Identifiants
pubmed: 34246947
pii: S0165-0327(21)00659-5
doi: 10.1016/j.jad.2021.06.073
pmc: PMC8712560
pii:
doi:
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
391-398Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Brain Behav Immun. 2020 Oct;89:531-542
pubmed: 32485289
BMC Psychiatry. 2017 Mar 20;17(1):97
pubmed: 28320380
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Global Spine J. 2020 Aug;10(5):534-552
pubmed: 32677575
Brain Behav Immun. 2020 Aug;88:901-907
pubmed: 32437915
Int J Soc Psychiatry. 2021 Aug;67(5):550-558
pubmed: 33040668
Psychiatry Res. 2020 Sep;291:113174
pubmed: 32585436
Blood Purif. 2021;50(2):257-260
pubmed: 32594085
Community Ment Health J. 2020 Jul;56(5):786-792
pubmed: 32378126
Neurosci Biobehav Rev. 2017 Mar;74(Pt B):321-329
pubmed: 27397854
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jan 10;104:110062
pubmed: 32771337
Psychiatry Res. 2020 Aug;290:113130
pubmed: 32497969
Asian J Psychiatr. 2020 Jun;51:102111
pubmed: 32361388
Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):241-247
pubmed: 32342698
BMJ Open. 2020 Oct 10;10(10):e042030
pubmed: 33040019
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Apr 20;107:110244
pubmed: 33453320
Ann Intern Med. 2020 Aug 18;173(4):317-320
pubmed: 32251513
Iran J Psychiatry. 2020 Jul;15(3):228-235
pubmed: 33193771
Ann Med Surg (Lond). 2020 Jul 18;57:70-75
pubmed: 32704368
Aust N Z J Psychiatry. 2006 Sep;40(9):790-6
pubmed: 16911755
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Brain Behav Immun Health. 2020 Oct;8:100144
pubmed: 32959031
Int J Rheum Dis. 2012 Apr;15(2):129-35
pubmed: 22462415
Asian J Psychiatr. 2020 Jun;51:102119
pubmed: 32339895
BJPsych Open. 2020 Oct 08;6(6):e116
pubmed: 33028449
J Med Internet Res. 2021 Feb 18;23(2):e25232
pubmed: 33556033
Int J Environ Res Public Health. 2020 Aug 26;17(17):
pubmed: 32858810
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Mar 2;106:110070
pubmed: 32800868
JAMA Netw Open. 2020 Mar 2;3(3):e203976
pubmed: 32202646
Br J Psychiatry. 2001 Nov;179:417-25
pubmed: 11689399